Skip to main content

Main navigation

EN BM 中文

EN BM 中文

Understanding

Understanding
Risk & Examination

Risk & Examination
Treating

Treating
Patient Adherence

Patient Adherence
Side effects

Side effects
- OSD
  
  OSD
- PAPS
  
  PAPS
- EN BM 中文
Support

Support
EN BM 中文

CONTACT US

SANTEN PHARMA MALAYSIA

(1117719-T)
Unit #23-A-10, Q Sental 2, Kuala Lumpur Sentral,
50470 Kuala Lumpur, MALAYSIA
Tel : +603-2276 3333
Fax: +603-2276 1333

Artwork Approval No: NP-GLAU-MY-0018
Copyright © [current-date:custom:Y] Santen Pharma Malaysia Sdn. Bhd. All Rights Reserved.

Disclaimer
Legal
Personal Data Protection Policy
Contact Us

*1 National Eye Institute – Glaucoma Facts, 2016
*2 Asia Pacific Glaucoma Guideline, 2008
*3 Glaucoma Research Foundation – Understanding and Living with Glaucoma, 2016
*4 Baudouin C. et al. Detrimental effect of preservatives in eyedrops: implications for the treatment of glaucoma. Acta Ophthal. 2008; 86: 716-726
*5 Bpyd K. McKinney JK. “Who is at Risk for Glaucoma?”. American Academy of Ophthalmology. 2015. Web July 12, 2016.
*6 Glaucoma Research Foundation – Care and Treatment
*7 Prevent Blindness. 2016. Available from: www.preventblindness.org/living-glaucoma
*8 Weinreb RN, et al. The pathophysiology and treatment of glaucoma, a review. JAMA. 2014;311(8):1901-1911.
*9 US National Library of Medicine. National Institutes of Health.
*10 Robin A, Grover DS. Compliance and adherence in glaucoma management. Indian J Ophthalmol. 2011;59 Suppl(Suppl1):S93–S96.
*11 G.F. Schwartz, H.A. Quigley. Adherence and persistence with glaucoma therapy Surv. Ophthalmol., 53 (Suppl 1) (2008), pp. S57-S68
*12 Br J Ophthalmol. 2007 Nov; 91(11): 1422–1424.
*13. Ramli, N., Supramaniam, G., Samsudin, A., Juana, A., Zahari, M., & Choo, M. M. (2015). Ocular Surface Disease in Glaucoma. Optometry and Vision Science, 92(9), e222–e226. https://doi.org/10.1097/opx.0000000000000542
*14. Leung, E. W., Medeiros, F. A., & Weinreb, R. N. (2008). Prevalence of Ocular Surface Disease in Glaucoma Patients. Journal of Glaucoma, 17(5), 350-355. doi:10.1097/ijg.0b013e31815c5f4f
*15. Barisic, F. (2014). Prevalence of Ocular Surface Disease in Patients with Glaucoma using Topical Antiglaucoma Medications. Journal of Clinical & Experimental Ophthalmology, 05(02). doi:10.4172/2155-9570.1000334
*16. The Epidemiology of Dry Eye Disease: Report of the Epidemiology Subcommittee of the International Dry Eye WorkShop (2007). (2007). The Ocular Surface, 5(2), 93-107. doi:10.1016/s1542-0124(12)70082-4
*17. Erb, C., Gast, U., & Schremmer, D. (2008). German register for glaucoma patients with dry eye. I. Basic outcome with respect to dry eye. Graefes Archive for Clinical and Experimental Ophthalmology, 246(11), 1593-1601. doi:10.1007/s00417-008-0881-9
*18. Freeman, P. D., & Kahook, M. Y. (2009). Preservatives in topical ophthalmic medications: historical and clinical perspectives. Expert Review of Ophthalmology, 4(1), 59–64. https://doi.org/10.1586/17469899.4.1.59
*19. Cristina, C. M., Simona, B., & Mirela, T. (2015). PRESERVATIVES FROM THE EYE DROPS AND THE OCULAR SURFACE. Romanian Journal of Ophthalmology, 59(1), January-March 2015, 2-5.
*20. Thygesen, J. (2018, April 13). Glaucoma therapy: Preservative-free for all?: OPTH. Retrieved from https://www.dove press.com/glaucoma-therapy-preservative-free-for-all-peer-reviewed-article-OPTH
*21. Pharmaceuticals, S. (2018, December 29). Glaucoma and the Burden of Ocular Surface Disease. Retrieved from https://the ophthalmologist.com/subspecialties/glaucoma-and-the-burden-of-ocular-surface-disease